Insulin treatment and GLP-1 receptor agonists work together, lead to steady glucose levels all day long, lower the risk of weight gain and hypoglycemia, and decrease the risk of long-term complications [2,5,6,19]. The gene discussed is INS; the disease is Hypoglycemia.